EYES, +24.63% shot up 30.7% to $15.38 on volume of 56.6 million shares in morning trading Tuesday, bringing its three-day gain to 975.5%, in the wake of the company's announcement that the Food and Drug Administration approved its Argus 2s Retinal Prosthesis System for the treatment of retinitis pigmentosa.
The stock skyrocketed a record 304.9% on record volume of 739.7 million shares on March 5 after the announcement, then 103.3% on volume of 320.4 million shares on Monday, before Tuesday's gain.
The stock had closed at a near 3-month low of $1.43 prior to the rally.
On Tuesday, the stock had been up as much as 69.9% at an intraday high of $20.00, the highest price seen since February 2018, before paring gains.
Separately, Paris-based Pixium Vision S.A. ALPIX, -11.87%issued a release saying the business combination with Second Sight announced on Jan. 6 continues.
Second Sight's stock has advanced 339.4% over the past 12 months, while the S&P 500 SPX, +2.10% has gained 41.6%.
- Second Sight Soars After FDA Approves Eye-Disease TreatmentTheStreet
- EYES Stock Price Increases Over 30% Pre-Market: Why It HappenedPulse 2.0
- Second Sight Medical stock skyrockets 8-fold in 2 days after FDA approves retinal prosthesis systemMarketWatch
- EYES Stock: Second Sight Flies on FDA ApprovalCNA Finance
- Second Sight Medical Products (EYES) Soars 305% in a Wild Day: Will It Hit $10?Own Snap
- Why Second Sight Medical Products, Inc. (EYES) rallied today?Park Telegraph
- Is Second Sight Medical Products Inc (EYES) Stock at the Top of the Medical Devices Industry?InvestorsObserver
- Investors Seeing Green as FDA Approves Second Sight Medical's Argus 2s Retinal Prosthesis SystemInvestorIdeas.com
- Continuation of the business combination project between Pixium Vision et Second Sight Medical ProductsGlobeNewswire
